Dr. Jun Wu is the Founder and Chairman of Cenova Capital, one of the earliest healthcare-specific investment firms in China. Since 2010, Cenova has four funds under management, with a combined AUM of more than USD650 million.
After almost fifteen years of life science research experience in United States, Dr. Wu went back to China in 2001 and co-founded Shanghai Genomics, one of the earliest biotech companies in China, and grew it to become one of the most successful biotech companies established by returnees. The company was the first China biotech listed on a major international stock exchange (TSE, 2007), and subsequently successfully developed a billion-dollar drug (pirfenidone) in China.
In addition to Dr. Wu’s investment career and entrepreneurial experience in China’s healthcare industry, he has also made important contributions in the field of immuno-oncology and has published over thirty high-quality research papers in professional journals, including Science, Nature, Nature Genetics. He was a lead investigator of many major government research programs and a recipient of the prestigious ‘National Outstanding Young Scientist Award’ from the Chinese National Science Foundation.
Dr. Wu has a Ph.D. from the University of California San Francisco and studied at Fudan University Medical School. He has been a long-term advisor to government healthcare policy-makers and is one of the first batch of government backed healthcare investors to facilitate the transformation of China’s healthcare industry.